AbbVie fibroids drug meets Phase 3 endpoint; CDER in warning letter frenzy as pharma struggles with quality control; HIV patients claim CVS steered beneficiaries to its pharmacies; Spark lays groundwork for US Luxturna launch
While the FDA issued significantly fewer warning letters in 2017, the number coming from its CDER unit has nearly doubled since 2014, says a new PwC report.
The BioPharma Dive Brand Studio teamed up with Catalent to survey hundreds of executives and key stakeholders in the clinical trial space. For access to the survey results, download the free report.
A federal judge ruled against Merck's patent for hepatitis C treatment. While the big pharma plans to appeal, it's a noteworthy win for Gilead in the meantime.
Investors, stakeholders, providers…robots. The only voice missing from healthcare AI discussions? The patient’s. Until now. Syneos Health™ surveyed 800 patients to understand their hopes and fears when it comes to facing a healthcare future with AI. Get insights on how AI can play a role in support, adherence, clinical trials, and at the pharmacy
here.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.